Fractyl Health increased its Board size from nine to ten members and appointed Michael Wartell as a Class III independent director, effective November 2, 2026. His term expires at the 2027 annual meeting. Under his Director Agreement, Wartell receives $40,000 per month in cash compensation payable in advance, with a three-month minimum payout if he resigns early, plus $3,000 for days exceeding four hours of board commitments outside normal duties. He will not participate in the company's standard Non-Employee Director Compensation Policy and is not currently assigned to any board committees. Fractyl Health operates in the healthcare sector, developing therapies for metabolic diseases.
